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INVESTORS GRANT SOURCES
Genocea Background
• Location: Cambridge, MA
• Platform: Licensed from Harvard Medical School, UC Berkeley
• Headcount: 35 (19 with MS, PhD, or MD)
• Funding: $61 million in venture and $6.7 million grant funding
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Antigen Discovery Platform (ATLAS™)
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The Problem:  A New Approach Needed for T Cell Vaccines
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Conventional Antigen Discovery Is Not Applicable to T cell Antigens
• Ab targets are surface exposed or secreted; T cell targets are any protein
• Too many targets for complex organisms: need rapid screening method
• T cell antigen discovery needs to account for HLA restriction
555
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response 
profiling
validation
screening
validation
NUMBER OF ANTIGENS
Thousands Dozens Leads Vaccine
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Clinical basis for 
Human Immune Response Profiling
Define
disease cohorts
Recruit subjects,
Collect PBMCs
Effective 
Immune 
Response Key Considerations
Output
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identifying 
immune response 
differences
Ineffective 
Immune 
Response
Deleterious 
or Negative 
Sequellae
• HLA diversity
• Age
• Gender
• Cohort size needed 
for statistical power
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ATLAS™ Workflow
• High-throughput protein screening of any disease-causing agent 
to identify protective T cell antigens* for effective vaccines
Seed Autologous APC
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*ATLAS™ discovers FULL  PROTEIN  
ANTIGENS, not epitopes, that are 
broadly seen across diverse 
human populations
Assay Supernatant 
for Cytokine(s) of 
interest
Add Sorted CD4+
or CD8+ T cells
Add Bacteria
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CD4+ and CD8+
High-Throughput Screening
Screen pathogen proteome through 
each patient’s APCs
Output
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E. coli expressing 
target antigen alone
CD8+
CTL
CD4+
Helper 
T Cell
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response 
per antigen, 
per subject
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• Frequency
• Magnitude
• Phenotype
in silico and in vivo Validation
Evaluate Protective versus 
Non-Protective Antigens
Filter Antigens 
for Vaccine Utility
• Low homology to self  & commensal organisms
• High homology across strains/species of pathogen
• Ability to produce recombinantly
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Validate Lead Antigens
in vivo 
• Established animal models
• Proof of mechanism
• Proof of concept
Final Vaccine
1010
ATLAS™ Advantages
• Comprehensive
– Full pathogen proteome
– Broad population coverage
• Validated
– Antigens discovered in the context of natural human protection
– Protective antigens discovered in each disease attempted
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• Broadly Applicable
– Multiple pathogen types and proteome sizes
– Potential applicability outside infectious disease
• Fast
– Time to first protective antigen discovery < 2 years
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The Genocea Pipeline
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Chlamydia
Pneumococcus
Malaria
Final vaccine formulation IND
Streptococcus pneumoniae Vaccine
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Next Generation Pneumococcal Vaccine: The Needs
1. Expand serotype coverage; avoid replacement
2. Increase and broaden efficacy at mucosal level 
a. Otitis media 
b. Colonization 
c. Indirect immunity 
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3. Improve efficacy for pneumococcal pneumonia in elderly 
4. Simpler and lower cost to manufacture → increase supply 
and global access 
5. Back-up, if PCVs are poorly effective, e.g. type 3
1414
T cells Prevent Nasopharyngeal Colonization of S. pneumoniae
Immunize mice i.n. 
with unencapsulated, 
killed S. pneumoniae
(WCV) plus CT
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Challenge i.n. with 
live, encapsulated  
S. pneumoniae
10 wks
Malley et al., (2005) PNAS 102:13
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Genocea Can Identify Antigens That Induce IL-17A After Natural Exposure
Locus/ 
Mechanism of Action
Consequences of 
Pneumococcal Disease
• Nasopharyngeal                
colonization
• Otitis media
Genocea Antigens
(TH17 CD4
+
T cell-mediated)
• Conserved
Vaccine Technology IV     |     May 20-25, 2012     |     Albufeira, Portugal
http://www.ohiohealth.com/
http://www.childrenscentralcal.org/HealthE/P02948/Pages/P02950.aspx
• Pneumonia
• Bacteremia
• Meningitis
PCVs and PPSVs
(antibody-mediated)
• Protect against colonization
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• Expression library constructed 
containing >99% of the predicted 
genes in pneumococcus  (2,242 
clones)
– Base library provided by Pathogen 
Functional Genomic Resource 
Built a Pneumococcal Expression Library 
That Covers 96% of Proteome
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Center (PFGRC)
• Full length protein expression 
detected for 96% of the proteome 
by assaying for an epitope tag on 
the C-terminus of each clone
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% relative expression = response in the test sample divided by the response to the minimal epitope-pulsed positive control
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Pneumococcus TH17 Antigen Discovery
• Screened full expression library with T cells derived from:
– WCV-immunized mice
– Healthy adult human donors 
• Developed method for enriching Pneumococcus-specific TH17 cells 
from human peripheral blood
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• Developed a robust pooling strategy to limit number of required 
human cells
• Identified antigens by measuring specific IL-17A secretion from CD4+ T 
cells
1818
Dual pooled screening method enables 
screening of  large proteomes
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Pools with the same colored symbol contain the same library clone
• Each clone present in two unique pools of four clones in the library
• Both pools must be above the threshold for a positive response
• Reduces the number of human cells needed for the screen
• Increases the statistical power of each screen
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Hit to Lead Selection Approach for Pneumococcus Antigens
• Frequency
• Phenotype
Antigens from Human and Mouse 
Screens
Filter Antigens 
for Vaccine Utility
• Low homology to self antigens
• < 30% seq. identity to sequenced gut flora
• > 95% seq. identity among sequenced SPN 
strains
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Validate Lead Antigens 
in vivo 
• Ability to recombinantly produce antigen
Select priority antigens based on:
• Ability to induce TH17 in mice
• Ability to protect in colonization models
• Ability to protect in sepsis models
GB104
GB144
GB152
2020
Lead Antigens Demonstrate Protection & Prevent Colonization 
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SPAg1 in an antigen chosen from the literature that was NOT 
identified as an antigen in Genocea library screens
WCA = whole cell vaccine – positive control
CT = adjuvant alone
003 = irrelevant HIS-tagged antigen
OVA = irrelevant antigen
negative controls
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• Mice immunized with a 
combination of GB104, 
GB144 and CT
• Anti-CD4, anti-IL-17 or 
isotype control antibodies 
administered prior to 
IL-17 and CD4+ T cells are essential for protection
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challenge
• CD4 depletion or 
neutralization of IL-17 
abrogates immunity to 
colonization
GB104 + GB144 + CT immunized
2222
• Antigens were first chosen 
based on human and mouse 
screening data
• Final vaccine candidates 
nominated after repeatable 
protection in colonization 
Top Antigens – Nomination Based on i.n. Vaccination Data
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model after i.n. administration 
with CT
• Goal is parenteral 
administration – alum chosen:
– Induced systemic IL-17A
– Induced robust IgG
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Percent of mice protected from colonization
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Antigen Combination with Alum Protects against Colonization
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*p<0.05; ***p<0.005
• Results
– GB144 alone was protective against colonization with 45% efficacy
– Trivalent formulation showed maximum efficacy
0.1
GB144 GB144 +
GB152
GB144 +
GB152 +
mGB104
WCA-
Alum
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Triple Combination Results Repeated in Several Studies
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Alum + GB104 + GB144 + GB152
Alum + GB104 + GB144 + GB152
* Usual Dose:  1µg GB144, 10µg each GB104 & GB152
** 100pmol:  2µg GB144, 3µg GB104, 8µg GB152
GB152
Study Median Alum CFU Median Test Group CFU Log Reduction % Protected
957 71.3 0.8 2.0 89
966 26.5 0.8 1.5 80
967 20.0 0.8 1.4 60
972 38.5 0.8 1.7 80
973 74.5 2.4 1.5 40
977 153.9 0.8 2.3 70
977 (low dose) 153.9 0.8 2.3 60
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Pre-clinical Development Summary
• Three novel antigens that are protective
– Intranasally with cholera toxin
– Parenterally with alum
• One antigen adsorbed to alum is protective against sepsis when 
administered parenterally (data not shown)
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• Combination antigen studies are underway to
– Demonstrate efficacy with optimal combination of antigens against IPD
– Identify appropriate B cell antigens for possible inclusion in final formulation
– Titrate appropriate doses of each antigen alone and in combination
• Protein characterization and purification methods are in development
2626
Genocea Pneumococcus Vaccine is Unique
Features
Genocea 
Program
Potential Benefit
Proteins conserved across all 
sequenced variants

• Protect against all Pneumococcus
strains
Colonization protection 
• Work upstream of, or together with, 
existing vaccines
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Sepsis protection () • Protect like current vaccines
Works with 
approved adjuvant

• Simpler regulatory path
• Lower downstream costs
Intramuscular
route of administration
 • Ease of administration
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